NK cells mediate clearance of CD8 <sup>+</sup> T cell–resistant tumors in response to STING agonists

Christopher J. Nicolai; Natalie K. Wolf; I-Chang Chang; Georgia Kirn; Assaf Marcus; Chudi Ndubaku; Sarah M. McWhirter; David H Raulet

doi:10.1126/sciimmunol.aaz2738

Related publications

Preprint2025

Intra-Tumoral Treg Ablation Unleashes NK Cell-Mediated Control of CD8 T Cell-Resistant Tumors

Chenyu Zhang, Charles Chien, Eglė Jurgaitytė, K. Sakiyama, Alissa Bockman, Yeara Jo, Seung Won Lee, Stephanie Silveria, Elizabeth Andrews, Abigail Mende, Lily Zhang, K. Christopher García, Allon Wagner, Michel DuPage, David H Raulet

Article2021

584 Powerful synergistic effects of a STING agonist and the IL-2 superkine, H9, in eliciting NK and T cell responses against MHC I- and MHC I+ tumors

Natalie K. Wolf, Cristina Blaj, Lora K. Picton, Gail Snyder, Li Zhang, Christopher J. Nicolai, Chudi Ndubaku, Kelsey Sivick Gauthier, Sarah M. McWhirter, K. Christopher García, David H Raulet

Article2022

Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I–deficient and MHC I <sup>+</sup> tumors

Natalie K. Wolf, Cristina Blaj, Lora K. Picton, Gail Snyder, Li Zhang, Christopher J. Nicolai, Chudi Ndubaku, Sarah M. McWhirter, K. Christopher García, David H Raulet

Article2020

Combination therapy to enhance NK cell anti-tumor responses

Natalie K. Wolf, Chris J. Nicolai, Susanna M. Dang, Gail Synder, Cristina Blaj, Sarah M. McWhirter, Lora K. Picton, K. Christopher García, David H Raulet

Article2021

Abstract IA05: Innate immune defenses against cancer: Potential for mobilizing NK cells for cancer immunotherapy

David H Raulet